Non-Covalent BTK Inhibitors in the Treatment of CLL: Pirtobrutinib

News
Video

Catherine Coombs, MD, and Alexey Danilov, MD, PhD, discuss data on the investigational non-covalent BTK inhibitor pirtobrutinib for the treatment of CLL.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
      Novel BTK Degrader Shows Activity in CLL/SLL Regardless of Mutation Status
      More Research Needed to Ascertain Ziftomenib’s Mechanism of Action in AML
      More Research Needed to Ascertain Ziftomenib’s Mechanism of Action in AML
      Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
      CLL Workshop Emphasizes Engaging Conversations on Shared Treatment Planning
      Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
      Navigating Treatment Decision-Making Challenges in CLL Management
      Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
      Asciminib Appears to Benefit All Chronic Myeloid Leukemia Subgroups
      Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
      Undetected MRD Confers Improved PFS With Ibrutinib Combo in CLL/SLL
      A panel of 3 experts on CML
      Advancing CML Management Towards an Ideal Patient Journey
      A panel of 3 experts on CML
      Ensuring Informed CML Care from Diagnosis Onward
      A panel of 3 experts on CML
      CML Treatment: Scenarios that Necessitate Switching Therapy
      A panel of 3 experts on CML
      When CML Therapy Shifts: Collaborative Approaches to Treatment Changes
      Related Content
      The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

      FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

      Russ Conroy
      June 25th 2025
      Article

      The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

      Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

      Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

      Elizabeth Shpall, MD
      May 29th 2019
      Podcast

      Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

      Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

      Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

      Jax DiEugenio
      June 17th 2025
      Article

      Single-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.

      Immunotherapy Approaches in AML

      Immunotherapy Approaches in AML

      Naval Daver, MD
      January 17th 2019
      Podcast

      Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

      Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.

      Oral Venetoclax Combo Elicits Responses, Survival in Newly Diagnosed AML

      Gina Mauro
      June 15th 2025
      Article

      Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.

      Dasatinib Misses Survival End Points in Core-Binding Factor AML

      Dasatinib Misses Survival End Points in Core-Binding Factor AML

      Ariana Pelosci
      June 14th 2025
      Article

      Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.